课题基金 / 基金详情

Identifying the target of CD44 monoclonal antibodies in the amelioration of murine immune thrombocytopenia using human-CD44 and Cre recombinase mouse models

Identifying the target of CD44 monoclonal antibodies in the amelioration of murine immune thrombocytopenia using human-CD44 and Cre recombinase mouse models
使用人 CD44 和 Cre 重组酶小鼠模型确定 CD44 单克隆抗体改善小鼠免疫性血小板减少症的靶标
批准号：
386479
负责人：
Kaur Gurleen
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-12-01 至 2018-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=386479&lang=en
关键词：
Autoimmune Diseases Cd44 Monoclonal Antibodies Cre Recombinase Mice Immune Thrombocytopenia Immunotherapies Innate Immune Cells Intravenous Immunoglobulin Platelets Transgenic Mice

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Intravenous immunoglobulin (IVIg) is the current treatment for a whole host of autoimmune and inflammatory disorders, including immune thrombocytopenia (ITP) which is a disorder characterized by low platelets. However, replacements for IVIg are necessary
期刊论文(0)
专著(0)
科研奖励(0)
会议论文